PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33272733-0 2021 Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease. Azathioprine 16-28 tumor necrosis factor Homo sapiens 66-75 33283312-8 2021 Predictors of infections in anti-TNFalpha-exposed patients were concomitant use of systemic steroids (OR 1.9, p=0.02) or azathioprine (OR 2.6, p=0.01) and a BMI<18.5 at time of infection (OR 2.2, p=0.01). Azathioprine 121-133 tumor necrosis factor Homo sapiens 33-41 33311945-10 2020 After adjustment for sex, age, type of IBD and latent TB, anti-TNFalpha with azathioprine increased the relative risk to 17.8 times more than conventional treatment. Azathioprine 77-89 tumor necrosis factor Homo sapiens 63-71 32689833-12 2020 In conclusion, our study suggests that maintaining therapeutic levels of anti-TNFalpha drugs without antibodies formation is feasible with lower doses of azathioprine, minimizing its side effects. Azathioprine 154-166 tumor necrosis factor Homo sapiens 78-86 32547497-14 2020 Using a personalized medicine approach, she was started on anti-(TNF)-alpha therapy with infliximab combined with azathioprine, which are indicated for treatment of CD. Azathioprine 114-126 tumor necrosis factor Homo sapiens 64-75 31980448-12 2020 CONCLUSION: In case of immune-mediated LOR to a first anti-TNF, AZA should be associated with the second anti-TNF. Azathioprine 64-67 tumor necrosis factor Homo sapiens 59-62 31980448-12 2020 CONCLUSION: In case of immune-mediated LOR to a first anti-TNF, AZA should be associated with the second anti-TNF. Azathioprine 64-67 tumor necrosis factor Homo sapiens 110-113 31532479-8 2020 Initial azathioprine remained the most cost-effective treatment on sensitivity analysis compared with infliximab and combination therapy, with 90% reductions in anti-TNF therapy costs and a 5-year time horizon, although combination therapy had an acceptable cost-effectiveness when costs were reduced in the extended model. Azathioprine 8-20 tumor necrosis factor Homo sapiens 166-169 31532479-10 2020 CONCLUSIONS: In the biosimilar era, initial azathioprine with escalation to infliximab appeared more cost-effective in the short term compared with infliximab or combination therapy, although initial combination therapy yields acceptable ICERs in the long term with continued reductions in anti-TNF therapy costs and will likely be the preferred treatment strategy in the future. Azathioprine 44-56 tumor necrosis factor Homo sapiens 295-298 29754190-18 2019 Anti-TNF-alpha drugs with or without immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) are often used for the induction and maintenance of remission. Azathioprine 55-67 tumor necrosis factor Homo sapiens 5-14 31694755-0 2019 Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Behcet"s disease with azathioprine. Azathioprine 88-100 tumor necrosis factor Homo sapiens 18-21 30748107-13 2019 Expression of TNF-alpha, IL-2, IL-4, IL-5, and IL-13 mRNA in the NPs treated by steroid, AZA, and 6-MP were significantly lower than those of the control (p < 0.001 for all). Azathioprine 89-92 tumor necrosis factor Homo sapiens 14-23 30889246-8 2019 Induction of autophagy with azathioprine correlated with the enhanced clearance of AIEC and dampened AIEC-induced increases in TNFalpha. Azathioprine 28-40 tumor necrosis factor Homo sapiens 127-135 28922253-14 2017 Antidrug antibody positivity rates were significantly higher throughout patients with previous anti-TNF exposure; concomitant azathioprine prevented antidrug antibody formation in anti-TNF-naive patients with CD. Azathioprine 126-138 tumor necrosis factor Homo sapiens 185-188 28679512-4 2017 We present the case of a patient who developed GBS while undergoing treatment with adalimumab in combination with azathioprine for severe fistulising Crohn"s disease, and review the literature on neurological adverse events that occur in association with anti-TNF therapy. Azathioprine 114-126 tumor necrosis factor Homo sapiens 260-263 26252649-11 2015 UC groups were compared and women treated with azathioprine showed reduction of total protein, globulin, ESR, and lymphocytes, with increased IL-6, TNF, IL-10, and TGF-beta. Azathioprine 47-59 tumor necrosis factor Homo sapiens 148-151 27548499-8 2016 An additional role for azathioprine in combo therapy with TNF antibodies has been indicated by several trials revealing a substantial benefit on response. Azathioprine 23-35 tumor necrosis factor Homo sapiens 58-61 28584644-8 2017 By comparison, the TNF-alpha mRNA expression level was evaluated in patients with a history of taking medications and demonstrated a significant association in the group that received the 5-ASA + Pred + AZA,5. Azathioprine 203-206 tumor necrosis factor Homo sapiens 19-28 25789922-0 2015 Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Azathioprine 19-31 tumor necrosis factor Homo sapiens 76-79 26557831-6 2015 In patients with chronic disease activity, treatment with anti-TNF antibodies has a higher level of evidence than azathioprine therapy and should therefore be preferred. Azathioprine 114-126 tumor necrosis factor Homo sapiens 63-66 25874518-0 2015 Azathioprine discontinuation earlier than 6 months in Crohn"s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Azathioprine 0-12 tumor necrosis factor Homo sapiens 95-98 25874518-0 2015 Azathioprine discontinuation earlier than 6 months in Crohn"s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Azathioprine 0-12 tumor necrosis factor Homo sapiens 165-168 25874518-8 2015 Factors associated with loss of response and therefore the need for anti-TNF dose escalation were azathioprine discontinuation earlier than 6 months and smoking. Azathioprine 98-110 tumor necrosis factor Homo sapiens 73-76 25874518-10 2015 CONCLUSION: Azathioprine discontinuation earlier than 6 months and smoking in CD patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Azathioprine 12-24 tumor necrosis factor Homo sapiens 106-109 25874518-10 2015 CONCLUSION: Azathioprine discontinuation earlier than 6 months and smoking in CD patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Azathioprine 12-24 tumor necrosis factor Homo sapiens 176-179 25789922-10 2015 CONCLUSIONS: Concomitant use of AZA/6 MP may decrease the occurrence of adverse skin lesions in patients receiving anti-TNF therapy. Azathioprine 32-35 tumor necrosis factor Homo sapiens 120-123 25182201-6 2014 Nonsteroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs, such as methotrexate or azathioprine, may be helpful; when patients are unresponsive to the combination of corticosteroids and immunosuppressant agents, the tumor necrosis factor-alpha inhibitor infliximab should be considered. Azathioprine 107-119 tumor necrosis factor Homo sapiens 240-267 25707965-4 2015 Compared to biologic monotherapy, concomitant use of immunomodulators (methotrexate, azathioprine, and 6-mercaptopurine) often increases the systemic exposure of the anti-TNFalpha agent and decreases the formation of antibodies to the anti-TNFalpha agent, consequently enhancing clinical efficacy. Azathioprine 85-97 tumor necrosis factor Homo sapiens 171-179 25707965-4 2015 Compared to biologic monotherapy, concomitant use of immunomodulators (methotrexate, azathioprine, and 6-mercaptopurine) often increases the systemic exposure of the anti-TNFalpha agent and decreases the formation of antibodies to the anti-TNFalpha agent, consequently enhancing clinical efficacy. Azathioprine 85-97 tumor necrosis factor Homo sapiens 240-248 25105206-9 2014 CONCLUSIONS: TB risk with anti-TNF agents appeared to be increased when these agents were used in combination with methotrexate or azathioprine as compared with monotherapy regimen. Azathioprine 131-143 tumor necrosis factor Homo sapiens 31-34 22853939-0 2012 Improvement of anti-TNFalpha antibody-induced pustular psoriasis by azathioprine. Azathioprine 68-80 tumor necrosis factor Homo sapiens 20-28 24884302-7 2014 When certolizumab pegol, infliximab, or adalimumab were collectively compared with azathioprine, patients initiated on an anti-TNF agent avoided further prescriptions for corticosteroids at a greater rate than patients receiving azathioprine at 12 (43% vs. 27%, respectively; P < 0.0001) and 24 months (33% vs. 23%, respectively; P = 0.028). Azathioprine 229-241 tumor necrosis factor Homo sapiens 127-130 24884302-8 2014 Individually, all anti-TNF agents showed higher rates of corticosteroid-sparing compared with azathioprine at 12 (P < 0.0001-0.011), but not 24 months (P = 0.0086-0.24). Azathioprine 94-106 tumor necrosis factor Homo sapiens 23-26 25531359-5 2014 Long-term follow up of patients in a single centre reported responders to azathioprine having a reduced risk of perianal surgery (OR = 0.36; 95% CI: 0.27-0.46), but complex perianal fistulising Crohn"s disease generally requires combination therapy with anti-TNF and azathioprine. Azathioprine 74-86 tumor necrosis factor Homo sapiens 259-262 24074969-3 2014 Immunosuppressive drugs such as azathioprine, cyclophosphamide and tumor necrosis factor blockers (anti-TNFalpha) are commonly used as second-line therapy with varying degrees of success. Azathioprine 32-44 tumor necrosis factor Homo sapiens 104-112 24379584-10 2013 Consistent with this observation, mesalazine and azathioprine induced, in primary fibroblasts, IL10RB and TNFRII over-expression and TNFRI and TNFalpha under-expression. Azathioprine 49-61 tumor necrosis factor Homo sapiens 143-151 18597652-2 2008 Many genetic variants have been studied in genes possibly involved in the metabolism or mechanism of action of therapeutic agents such as glucocorticosteroids, azathioprine/6-mercaptopurine, methotrexate, calcineurin inhibitors or anti-TNF agents. Azathioprine 160-172 tumor necrosis factor Homo sapiens 236-239 20120429-4 2010 This patient has remained clear for two years with this combination and has tolerated a tapering of the azathioprine from the initial dose of 250 mg. Etanercept is a recombinant human dimeric fusion protein which acts as a competitive inhibitor of TNF-alpha by binding to both soluble and receptor-bound molecules of TNF-alpha. Azathioprine 104-116 tumor necrosis factor Homo sapiens 248-257 20926883-12 2010 Strategies to reduce immunogenicity of anti-TNF agents include combination therapy with azathioprine and administration of a loading dose followed by systematic maintenance dosing. Azathioprine 88-100 tumor necrosis factor Homo sapiens 44-47 19584951-8 2009 Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment. Azathioprine 15-27 tumor necrosis factor Homo sapiens 151-159 17149058-6 2006 Tumor necrosis factor (TNF) inhibitors such as infliximab or etanercept should be considered as the next step in the treatment if azathioprine or methotrexate fails. Azathioprine 130-142 tumor necrosis factor Homo sapiens 0-21 17713889-8 2007 More recent anti TNF-alpha antibodies can be applied without an azathioprine comedication. Azathioprine 64-76 tumor necrosis factor Homo sapiens 17-26 17149058-6 2006 Tumor necrosis factor (TNF) inhibitors such as infliximab or etanercept should be considered as the next step in the treatment if azathioprine or methotrexate fails. Azathioprine 130-142 tumor necrosis factor Homo sapiens 23-26 17110316-5 2006 Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Azathioprine 109-121 tumor necrosis factor Homo sapiens 130-133 9762674-4 1998 When cytokine levels were analysed independently from MS clinical activity, the use of AZA inhibited IgG OB and TNF-alpha synthesis (P = 0.002) but increased IL-4 (P = 0.0024), whereas IFN-beta 1a stimulated TNF-alpha and inhibited IgG OB and IL-4 production. Azathioprine 87-90 tumor necrosis factor Homo sapiens 112-121 14614765-6 2003 Other agents that nonspecifically inhibit TNFalpha release include methotrexate, azathioprine and pentoxifylline. Azathioprine 81-93 tumor necrosis factor Homo sapiens 42-50 10631636-3 1999 Statistical correlations significantly showed that: (a) AZA lowers TNF-alpha (P = 0.002) and increases IL-4 production (P = 0.0024), and IFN-beta 1 a increases TNF-alpha and decreases IL-4 levels; (b) CST has a negative effect on TNF-alpha, IL-6, and IL-4 synthesis; and (c) AZA, IFN-beta 1 a, and CST diminish IgG OB synthesis (P = 0.001). Azathioprine 56-59 tumor necrosis factor Homo sapiens 67-76 11354662-0 2001 Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro. Azathioprine 0-3 tumor necrosis factor Homo sapiens 72-99 9762674-4 1998 When cytokine levels were analysed independently from MS clinical activity, the use of AZA inhibited IgG OB and TNF-alpha synthesis (P = 0.002) but increased IL-4 (P = 0.0024), whereas IFN-beta 1a stimulated TNF-alpha and inhibited IgG OB and IL-4 production. Azathioprine 87-90 tumor necrosis factor Homo sapiens 208-217 7694584-4 1993 We found that dexamethasone (4-40 micrograms/mL), the azathioprine metabolite 6-mercaptopurine (10-100 micrograms/mL) and cyclosporine A (0.1-1 microgram/mL) have no effect on the basal and the tumor necrosis factor-alpha- or interleukin-1-stimulated expression of these adhesion molecules. Azathioprine 54-66 tumor necrosis factor Homo sapiens 194-221 9050957-5 1997 The decrease in TNF-alpha levels and the increase in "suppressor-inducer" lymphocytes could reduce chronic inflammation in multiple sclerosis, and paralleled an overall favourable clinical response to azathioprine treatment in our patients. Azathioprine 201-213 tumor necrosis factor Homo sapiens 16-25 34474172-12 2022 Combination of anti-TNF with immunomodulators (azathioprine, 6-meracptopurine, methotrexate) resulted in an attenuated vaccine response as compared to anti-TNF monotherapy. Azathioprine 47-59 tumor necrosis factor Homo sapiens 20-23 34474172-12 2022 Combination of anti-TNF with immunomodulators (azathioprine, 6-meracptopurine, methotrexate) resulted in an attenuated vaccine response as compared to anti-TNF monotherapy. Azathioprine 47-59 tumor necrosis factor Homo sapiens 156-159